After subcutaneous injection of the vaccine to evaluate its therapeutic effect in the bearing B16F10 mouse model, CD8+ T-cell responses and anti-OVA antibodies were produced in mice, which resulted in a significant reduction in tumor size and lung metastases, indicating that MWNTs were able to remarkably improve the ability of co-loaded OVA, CpG and αCD40 to inhibit the growth of melanoma cells. The gene discussed is CD8A; the disease is neoplasm.